Ertugliflozin, a sodium glucose cotransporter-2 inhibitor, is approved in the United States for treatment of type 2 diabetes mellitus. A novel two-period study design with C microtracer dosing in each period was used to determine absolute oral bioavailability (F) and fraction absorbed (F ) of ertugliflozin. Eight healthy adult men received 100-μg i.
View Article and Find Full Text PDF